The COVID-19 Drug and Gene Set Library

Summary In a short period, many research publications that report sets of experimentally validated drugs as potential COVID-19 therapies have emerged. To organize this accumulating knowledge, we developed the COVID-19 Drug and Gene Set Library (https://amp.pharm.mssm.edu/covid19/), a collection of drug and gene sets related to COVID-19 research from multiple sources. The platform enables users to view, download, analyze, visualize, and contribute drug and gene sets related to COVID-19 research. To evaluate the content of the library, we compared the results from six in vitro drug screens for COVID-19 repurposing candidates. Surprisingly, we observe low overlap across screens while highlighting overlapping candidates that should receive more attention as potential therapeutics for COVID-19. Overall, the COVID-19 Drug and Gene Set Library can be used to identify community consensus, make researchers and clinicians aware of new potential therapies, enable machine-learning applications, and facilitate the research community to work together toward a cure.

[1]  A. Singanayagam,et al.  Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? , 2020, The Lancet.

[2]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[3]  S. Rajasekaran,et al.  Analysis of Infected Host Gene Expression Reveals Repurposed Drug Candidates and Time-Dependent Host Response Dynamics for COVID-19 , 2020, bioRxiv.

[4]  M. Bjørås,et al.  Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19 , 2020, bioRxiv.

[5]  Paul Shinn,et al.  Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs , 2014, Emerging Microbes & Infections.

[6]  Lars Juhl Jensen.  Tagger: BeCalm API for rapid named entity recognition , 2017 .

[7]  David Shum,et al.  Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.

[8]  Simon Lin,et al.  GeneRIF is a more comprehensive, current and computationally tractable source of gene-disease relationships than OMIM , 2006 .

[9]  Yolanda T. Chong,et al.  Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2 , 2020, bioRxiv.

[10]  Hualiang Jiang,et al.  Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.

[11]  C. Cava,et al.  In Silico Discovery of Candidate Drugs against Covid-19 , 2020, Viruses.

[12]  Peter G. Schultz,et al.  A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals , 2020, bioRxiv.

[13]  Zihe Rao,et al.  Structure of Mpro from COVID-19 virus and discovery of its inhibitors , 2020, medRxiv.

[14]  Andrew D. Rouillard,et al.  GEO2Enrichr: browser extension and server app to extract gene sets from GEO and analyze them for biological functions , 2015, Bioinform..

[15]  Angela N. Brooks,et al.  A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles , 2017, Cell.

[16]  George Papadatos,et al.  The ChEMBL database in 2017 , 2016, Nucleic Acids Res..

[17]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[18]  Kathleen M Jagodnik,et al.  Extraction and analysis of signatures from the Gene Expression Omnibus by the crowd , 2016, Nature Communications.

[19]  Andrew D. Rouillard,et al.  The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins , 2016, Database J. Biol. Databases Curation.

[20]  Denis Torre,et al.  BioJupies: Automated Generation of Interactive Notebooks for RNA-Seq Data Analysis in the Cloud. , 2018, Cell systems.

[21]  Andrew R. Leach,et al.  The Global Phosphorylation Landscape of SARS-CoV-2 Infection , 2020, Cell.

[22]  Motonori Ota,et al.  Knowledge‐based structural models of SARS‐CoV‐2 proteins and their complexes with potential drugs , 2020, FEBS letters.

[23]  R. N. Brogden,et al.  Mefloquine , 1993, Drugs.

[24]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[25]  Pierre Geurts,et al.  Extremely randomized trees , 2006, Machine Learning.

[26]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[27]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[28]  Denis Torre,et al.  Geneshot: search engine for ranking genes from arbitrary text queries , 2019, Nucleic Acids Res..

[29]  F. Alakwaa.  Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data , 2020, mSystems.

[30]  Jianyang Zeng,et al.  A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19 , 2020, bioRxiv.

[31]  B. Oakley,et al.  Faculty Opinions recommendation of A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[32]  R. Albrecht,et al.  SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems , 2020, bioRxiv.

[33]  Avi Ma'ayan,et al.  Drug-induced adverse events prediction with the LINCS L1000 data , 2016, Bioinform..

[34]  In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication , 2020, Scientific Reports.

[35]  Christopher. Simons,et al.  Machine learning with Python , 2017 .

[36]  Nikos Vasilakis,et al.  A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. , 2016, Cell host & microbe.

[37]  C. Mélot,et al.  Improvement in ventilation-perfusion matching by almitrine in COPD. , 1983, Chest.

[38]  Bruno Coutard,et al.  In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication , 2020, Scientific Reports.

[39]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[40]  B. Russ,et al.  Homology Modeling of TMPRSS2 Yields Candidate Drugs That May Inhibit Entry of SARS-CoV-2 into Human Cells , 2020 .

[41]  Kathleen M Jagodnik,et al.  Massive mining of publicly available RNA-seq data from human and mouse , 2017, Nature Communications.

[42]  Constancio González,et al.  Effects of almitrine bismesylate on the ionic currents of chemoreceptor cells from the carotid body. , 1998, Molecular pharmacology.

[43]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[44]  Trey Ideker,et al.  A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing , 2020, bioRxiv.

[45]  S. Rajasekaran,et al.  Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19. , 2020, bioRxiv : the preprint server for biology.

[46]  L. Guenther,et al.  Acitretin Use in Dermatology , 2017, Journal of cutaneous medicine and surgery.

[47]  Avi Ma'ayan,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[48]  M. Sherman,et al.  A Preliminary Report , 1953 .

[49]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[51]  W. Vischer,et al.  Lamprene (clofazimine) in leprosy. Basic information. , 1979, Leprosy review.